Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.

[1]  S. Ball,et al.  Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three‐year results from the UNCOVER‐3 study , 2018, Journal of the American Academy of Dermatology.

[2]  A. Kimball,et al.  Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. , 2018, Journal of drugs in dermatology : JDD.

[3]  M. Lebwohl,et al.  Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials , 2018, Journal of the American Academy of Dermatology.

[4]  L. Iversen,et al.  Efficacy and safety of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER‐3) , 2017, Journal of the American Academy of Dermatology.

[5]  T. Luger,et al.  Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study , 2017, The British journal of dermatology.

[6]  K. Reich,et al.  Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results. , 2017, Journal of Drugs in Dermatology.

[7]  A. Kimball,et al.  Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials , 2017, The Lancet.

[8]  A. Gottlieb,et al.  A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.

[9]  B. Strober,et al.  Clinical meaningfulness of complete skin clearance in psoriasis. , 2016, Journal of the American Academy of Dermatology.

[10]  H. Nakagawa,et al.  Long‐term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate‐to‐severe plaque psoriasis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  H. Nakagawa,et al.  Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. , 2016, Journal of dermatological science.

[12]  B. Strober,et al.  Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. , 2015, The New England journal of medicine.

[13]  J. Koo,et al.  Biologic fatigue in psoriasis , 2014, The Journal of dermatological treatment.

[14]  A. Kimball,et al.  Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  B. Strober,et al.  Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. , 2012, Journal of the American Academy of Dermatology.

[16]  A. Kimball,et al.  Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial through up to 3 years , 2012, The British journal of dermatology.